Manufacturer record
Cyper Pharma: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
12 batches manufactured by Cyper Pharma (Himachal Pradesh) were declared Not of Standard Quality between June 2021 and July 2023. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
12 records linked to Cyper Pharma in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Nimesulide and Paracetamol Tablets (CDNIM-P TABLETS) | SMP- 2205Mfg 2023-01 · Exp 2024-12 | Uniformity of weight and Assay of Nimesulide and ParacetamolAssay | RDTL ChandigarhState lab | Jul 2023 |
| Indomethacin Capsules IP (INDOMETHACIN CAPSULES) | IND-2202Mfg 2023-02 · Exp 2026-01 | Uniformity of weight and Assay of IndomethacinAssay | RDTL ChandigarhState lab | Jul 2023 |
| Griseofulvin Tablets IP 250 mg (Grisowin-250 Tablets) | GSP- 22B08Mfg 2023-01 · Exp 2024-12 | Uniformity of weight and Assay of GriseofulvinAssay | RDTL ChandigarhState lab | Jul 2023 |
| Calcium Carbonate with Vitamin D3 Tablets (CYPCAL-FORTE TABLETS) | CLF- 22013Mfg 2022-11 · Exp 2024-10 | Assay of Vitamin D3Assay | RDTL ChandigarhState lab | Jul 2023 |
| Ampicillin Capsules IP (ampicillin Capsules IP-250) | AMP- 22A07Mfg 2023-01 · Exp 2024-12 | Assay of Ampcillin Trihydrate calculated as AmpicillinAssay | RDTL ChandigarhState lab | Jul 2023 |
| Albendazole Tablets IP 400 mg | ABD-2206Mfg 2023-01 · Exp 2024-12 | DissolutionDissolution | RDTL ChandigarhState lab | Jul 2023 |
| Loperamide Hydrochloride Tablets IP (DYRIA STOP TABLETS) | DY?2214Mfg 2023-02 · Exp 2025-01 | Dissolution of Loperamide HydrochlorideDissolution | RDTL ChandigarhState lab | May 2023 |
| Doxycycline and Lactic Acid Bacillus Capsules (DOXYFIL-LB CAPSULES) | DXF?2103Mfg 2022-03 · Exp 2024-02 | Identification and Assay of Lactic Acid Bacillus.Assay | RDTL ChandigarhState lab | May 2023 |
| Chlorpheniramine Maleate Tablets IP 4 mg | CPM2205Mfg 2022-12 · Exp 2024-11 | Assay of Chlorpheniramine MaleateAssay | RDTL ChandigarhState lab | May 2023 |
| Cefixime and Ofloxacin Tablets (ZENCEF-O TABLETS) | ZFO?2101Mfg 2022-03 · Exp 2024-02 | Assay of Cefixime Trihydrate Calculated as anhydrous CefiximeAssay | RDTL ChandigarhState lab | May 2023 |
| Ibuprofen Tablets IP 200 mg | IB-22A01Mfg 2023-02 · Exp 2025-01 | DissolutionDissolution | RDTL ChandigarhState lab | Apr 2023 |
| AMPICILLIN CAPSULES I.P. 500 mg | AMP-19B03Mfg 2019-08 · Exp 2022-07 | AssayAssay | RDTL GuwahatiState lab | Jun 2021 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.